Does the media refer more to RGNX or MLTX?

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for REGENXBIO. MoonLake Immunotherapeutics' average media sentiment score of 1.24 beat REGENXBIO's score of 0.85 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, RGNX or SEPN?

Septerna has lower revenue, but higher earnings than REGENXBIO. Septerna is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.18 -$193.88M -$5.60 N/A Septerna $45.95M 29.46 -$48.88M -$0.81 N/A

Is RGNX or SEPN more profitable?

Septerna has a net margin of -49.88% compared to REGENXBIO's net margin of -330.23%. Septerna's return on equity of -12.72% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets REGENXBIO -330.23% -232.50% -61.02% Septerna -49.88% -12.72% -8.87%

Does the media favor RGNX or SEPN?

In the previous week, REGENXBIO and REGENXBIO both had 3 articles in the media. REGENXBIO's average media sentiment score of 0.85 beat Septerna's score of 0.55 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Septerna 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, HROW or RGNX?

Harrow has higher revenue and earnings than REGENXBIO. Harrow is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harrow $272.30M 4.67 -$5.14M -$0.41 N/A REGENXBIO $170.44M 2.18 -$193.88M -$5.60 N/A

Is HROW or RGNX more profitable?

Harrow has a net margin of -5.57% compared to REGENXBIO's net margin of -330.23%. Harrow's return on equity of 19.59% beat REGENXBIO's return on equity. Company Net Margins Return on Equity Return on Assets Harrow -5.57% 19.59% 2.26% REGENXBIO -330.23% -232.50% -61.02%

Does the media favor HROW or RGNX?

In the previous week, Harrow had 3 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for Harrow and 3 mentions for REGENXBIO. Harrow's average media sentiment score of 1.21 beat REGENXBIO's score of 0.85 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, RGNX or WVE?

REGENXBIO has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio REGENXBIO $170.44M 2.18 -$193.88M -$5.60 N/A WAVE Life Sciences $42.73M 28.16 -$204.38M -$1.06 N/A

Does the media refer more to RGNX or WVE?

In the previous week, WAVE Life Sciences had 3 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.85 beat WAVE Life Sciences' score of 0.32 indicating that REGENXBIO is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment REGENXBIO 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive WAVE Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

REGENXBIO (RGNX) Competitors

$7.18 +0.17 (+2.35%)

Closing price 03:59 PM Eastern

Extended Trading

$7.14 -0.03 (-0.42%)

As of 04:10 PM Eastern

Compare

RGNX vs. MLTX, SEPN, AVBP, HROW, and WVE

Should you buy REGENXBIO stock or one of its competitors? MarketBeat compares REGENXBIO with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with REGENXBIO include MoonLake Immunotherapeutics (MLTX), Septerna (SEPN), ArriVent BioPharma (AVBP), Harrow (HROW), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.

How does REGENXBIO compare to MoonLake Immunotherapeutics?

REGENXBIO (NASDAQ:RGNX) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, MoonLake Immunotherapeutics had 1 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 3 mentions for REGENXBIO. MoonLake Immunotherapeutics' average media sentiment score of 1.24 beat REGENXBIO's score of 0.85 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. MoonLake Immunotherapeutics' return on equity of -85.15% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

REGENXBIO has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.18	-$193.88M	-$5.60	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

REGENXBIO has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

REGENXBIO presently has a consensus target price of $23.91, indicating a potential upside of 233.23%. MoonLake Immunotherapeutics has a consensus target price of $23.85, indicating a potential upside of 26.67%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

88.1% of REGENXBIO shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 14.2% of REGENXBIO shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

MoonLake Immunotherapeutics beats REGENXBIO on 7 of the 13 factors compared between the two stocks.

How does REGENXBIO compare to Septerna?

REGENXBIO (NASDAQ:RGNX) and Septerna (NASDAQ:SEPN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

88.1% of REGENXBIO shares are held by institutional investors. 14.2% of REGENXBIO shares are held by insiders. Comparatively, 4.3% of Septerna shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, REGENXBIO and REGENXBIO both had 3 articles in the media. REGENXBIO's average media sentiment score of 0.85 beat Septerna's score of 0.55 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Septerna	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

REGENXBIO currently has a consensus price target of $23.91, suggesting a potential upside of 233.23%. Septerna has a consensus price target of $43.13, suggesting a potential upside of 43.63%. Given REGENXBIO's higher probable upside, equities analysts plainly believe REGENXBIO is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Septerna has a net margin of -49.88% compared to REGENXBIO's net margin of -330.23%. Septerna's return on equity of -12.72% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
Septerna	-49.88%	-12.72%	-8.87%

REGENXBIO has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Septerna has a beta of 2.39, indicating that its stock price is 139% more volatile than the broader market.

Septerna has lower revenue, but higher earnings than REGENXBIO. Septerna is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.18	-$193.88M	-$5.60	N/A
Septerna	$45.95M	29.46	-$48.88M	-$0.81	N/A

Summary

Septerna beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to ArriVent BioPharma?

REGENXBIO (NASDAQ:RGNX) and ArriVent BioPharma (NASDAQ:AVBP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

In the previous week, REGENXBIO had 2 more articles in the media than ArriVent BioPharma. MarketBeat recorded 3 mentions for REGENXBIO and 1 mentions for ArriVent BioPharma. ArriVent BioPharma's average media sentiment score of 1.87 beat REGENXBIO's score of 0.85 indicating that ArriVent BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
REGENXBIO	Positive
ArriVent BioPharma	Very Positive

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 9.5% of ArriVent BioPharma shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 8.6% of ArriVent BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

ArriVent BioPharma has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. ArriVent BioPharma's return on equity of -48.98% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
ArriVent BioPharma	N/A	-48.98%	-45.44%

REGENXBIO has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, ArriVent BioPharma has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market.

REGENXBIO presently has a consensus target price of $23.91, suggesting a potential upside of 233.23%. ArriVent BioPharma has a consensus target price of $43.38, suggesting a potential upside of 41.79%. Given REGENXBIO's higher probable upside, equities analysts clearly believe REGENXBIO is more favorable than ArriVent BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
ArriVent BioPharma	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

ArriVent BioPharma has lower revenue, but higher earnings than REGENXBIO. ArriVent BioPharma is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.18	-$193.88M	-$5.60	N/A
ArriVent BioPharma	N/A	N/A	-$166.31M	-$3.47	N/A

Summary

ArriVent BioPharma beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to Harrow?

Harrow (NASDAQ:HROW) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Harrow presently has a consensus target price of $69.43, indicating a potential upside of 103.70%. REGENXBIO has a consensus target price of $23.91, indicating a potential upside of 233.23%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts plainly believe REGENXBIO is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

Harrow has higher revenue and earnings than REGENXBIO. Harrow is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	4.67	-$5.14M	-$0.41	N/A
REGENXBIO	$170.44M	2.18	-$193.88M	-$5.60	N/A

In the previous week, Harrow had 3 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for Harrow and 3 mentions for REGENXBIO. Harrow's average media sentiment score of 1.21 beat REGENXBIO's score of 0.85 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Harrow has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market. Comparatively, REGENXBIO has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market.

72.8% of Harrow shares are held by institutional investors. Comparatively, 88.1% of REGENXBIO shares are held by institutional investors. 12.8% of Harrow shares are held by company insiders. Comparatively, 14.2% of REGENXBIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Harrow has a net margin of -5.57% compared to REGENXBIO's net margin of -330.23%. Harrow's return on equity of 19.59% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Harrow beats REGENXBIO on 9 of the 16 factors compared between the two stocks.

How does REGENXBIO compare to WAVE Life Sciences?

REGENXBIO (NASDAQ:RGNX) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

REGENXBIO has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.33, meaning that its stock price is 233% less volatile than the broader market.

REGENXBIO has higher revenue and earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
REGENXBIO	$170.44M	2.18	-$193.88M	-$5.60	N/A
WAVE Life Sciences	$42.73M	28.16	-$204.38M	-$1.06	N/A

In the previous week, WAVE Life Sciences had 3 more articles in the media than REGENXBIO. MarketBeat recorded 6 mentions for WAVE Life Sciences and 3 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.85 beat WAVE Life Sciences' score of 0.32 indicating that REGENXBIO is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
REGENXBIO	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
WAVE Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

REGENXBIO presently has a consensus target price of $23.91, suggesting a potential upside of 233.23%. WAVE Life Sciences has a consensus target price of $27.25, suggesting a potential upside of 335.65%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
REGENXBIO	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
WAVE Life Sciences	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.87

WAVE Life Sciences has a net margin of -255.70% compared to REGENXBIO's net margin of -330.23%. WAVE Life Sciences' return on equity of -56.76% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
REGENXBIO	-330.23%	-232.50%	-61.02%
WAVE Life Sciences	-255.70%	-56.76%	-42.80%

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

WAVE Life Sciences beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

Get REGENXBIO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGNX vs. The Competition

Export

Metric	REGENXBIO	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$370.95M	$3.32B	$6.31B	$12.61B
Dividend Yield	N/A	2.28%	2.68%	5.22%
P/E Ratio	-1.28	18.10	21.13	26.69
Price / Sales	2.18	327.47	546.80	115.09
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	3.53	6.85	9.95	6.90
Net Income	-$193.88M	$24.15M	$3.56B	$336.84M
7 Day Performance	12.99%	2.03%	2.15%	4.24%
1 Month Performance	N/A	N/A	N/A	-0.07%
1 Year Performance	-17.34%	63.17%	36.47%	40.32%

REGENXBIO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGNX REGENXBIO	3.4095 of 5 stars	$7.18 +2.4%	$23.91 +233.2%	-19.2%	$370.95M	$170.44M	N/A	370
MLTX MoonLake Immunotherapeutics	3.8711 of 5 stars	$18.19 flat	$23.85 +31.1%	-50.9%	$1.30B	N/A	N/A	2	Positive News
SEPN Septerna	2.3903 of 5 stars	$28.36 flat	$43.13 +52.1%	+221.3%	$1.28B	$45.95M	N/A	N/A	Gap Down
AVBP ArriVent BioPharma	2.5658 of 5 stars	$26.73 flat	$43.13 +61.3%	+42.8%	$1.24B	N/A	N/A	40	Positive News Analyst Forecast
HROW Harrow	4.6092 of 5 stars	$33.00 flat	$69.43 +110.4%	+24.7%	$1.23B	$272.30M	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGNX) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

REGENXBIO (RGNX) Competitors

RGNX vs. MLTX, SEPN, AVBP, HROW, and WVE

How does REGENXBIO compare to MoonLake Immunotherapeutics?

Summary

How does REGENXBIO compare to Septerna?

Summary

How does REGENXBIO compare to ArriVent BioPharma?

Summary

How does REGENXBIO compare to Harrow?

Summary

How does REGENXBIO compare to WAVE Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

REGENXBIO (RGNX) Competitors

RGNX vs. MLTX, SEPN, AVBP, HROW, and WVE

How does REGENXBIO compare to MoonLake Immunotherapeutics?

Does the media refer more to RGNX or MLTX?

Is RGNX or MLTX more profitable?

Which has better earnings and valuation, RGNX or MLTX?

Which has more volatility and risk, RGNX or MLTX?

Do analysts recommend RGNX or MLTX?

Do insiders and institutionals believe in RGNX or MLTX?

Summary

How does REGENXBIO compare to Septerna?

Do institutionals and insiders believe in RGNX or SEPN?

Does the media favor RGNX or SEPN?

Do analysts rate RGNX or SEPN?

Is RGNX or SEPN more profitable?

Which has more risk & volatility, RGNX or SEPN?

Which has higher earnings and valuation, RGNX or SEPN?

Summary

How does REGENXBIO compare to ArriVent BioPharma?

Does the media prefer RGNX or AVBP?

Do institutionals and insiders have more ownership in RGNX or AVBP?

Is RGNX or AVBP more profitable?

Which has more risk & volatility, RGNX or AVBP?

Do analysts recommend RGNX or AVBP?

Which has better earnings and valuation, RGNX or AVBP?

Summary

How does REGENXBIO compare to Harrow?

Do analysts prefer HROW or RGNX?

Which has preferable earnings & valuation, HROW or RGNX?

Does the media favor HROW or RGNX?

Which has more risk & volatility, HROW or RGNX?

Do insiders & institutionals believe in HROW or RGNX?

Is HROW or RGNX more profitable?

Summary

How does REGENXBIO compare to WAVE Life Sciences?

Which has more volatility & risk, RGNX or WVE?

Which has preferable earnings & valuation, RGNX or WVE?

Does the media refer more to RGNX or WVE?

Do analysts recommend RGNX or WVE?

Is RGNX or WVE more profitable?

Do institutionals & insiders hold more shares of RGNX or WVE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGNX vs. The Competition

REGENXBIO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools